Drew Deniger
2023
In 2023, Drew Deniger earned a total compensation of $629.7K as VP, Research and Development at ZIOPHARM Oncology, a 34% decrease compared to previous year.
Compensation breakdown
| Option Awards | $47,888 |
|---|---|
| Salary | $317,757 |
| Other | $264,035 |
| Total | $629,680 |
Deniger received $317.8K in salary, accounting for 50% of the total pay in 2023.
Deniger also received $47.9K in option awards and $264K in other compensation.
Rankings
In 2023, Drew Deniger's compensation ranked 1,688th out of 2,773 executives tracked by ExecPay. In other words, Deniger earned more than 39.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,688 out of 2,773 | 39th |
Division Manufacturing | 984 out of 1,516 | 35th |
Major group Chemicals And Allied Products | 621 out of 855 | 27th |
Industry group Drugs | 605 out of 821 | 26th |
Industry Pharmaceutical Preparations | 430 out of 590 | 27th |
Source: SEC filing on April 26, 2024.
Deniger's colleagues
We found two more compensation records of executives who worked with Drew Deniger at ZIOPHARM Oncology in 2023.